Uhl et al identified laboratory findings that may predict bleeding in patients undergoing cancer therapy. The authors are from Harvard Medical School, Beth Israel Deaconess Medical Center, New England Research Institutes, the University of Washington, Seattle Cancer Care Alliance and Bloodworks Northwest.
Outcome: bleeding grade >= 2A
More significant impact
(1) platelet count <= 5,000 per µL(odds ratio 3.1)
(2) platelet count 6,000 to 80,000 per µL for a patient with allogeneic stem cell transplant or chemotherapy (odds ratio not specified; based on Figure 2 and Table 3 will arbitrarily set it to 2 for the implementation)
(3) aPTT > 50 seconds (odds ratio 2.3)
(4) INR > 1.5 (odds ratio 2.1)
Less significant impact:
(1) hematocrit <= 25% (odds ratio 1.3)
(2) aPTT 30 to 50 seconds (odds ratio 1.4)
(3) INR 1.2 to 1.5 (odds ratio 1.5)
To read more or access our algorithms and calculators, please log in or register.
